Vedolizumab
- Product Name
- Vedolizumab
- CAS No.
- 943609-66-3
- Chemical Name
- Vedolizumab
- Synonyms
- Vedolizumab;Vedolizumab USP/EP/BP;Vedolizumab 62.6mg/ml;Research Grade Vedolizumab;Vedolizumab (anti-α4β7-integrin);Research Grade Vedolizumab(DHC98802)
- CBNumber
- CB54187577
- Formula Weight
- 0
- MOL File
- Mol file
Vedolizumab Property
- storage temp.
- Store at -80°C
- solubility
- Soluble in DMSO
- form
- Solid
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- CS-7825
- Product name
- Vedolizumab
- Purity
- 99.64%
- Packaging
- 1mg
- Price
- $400
- Updated
- 2021/12/16
- Product number
- BV165597
- Product name
- Vedolizumab
- Packaging
- 1mg
- Price
- $600
- Updated
- 2021/12/16
- Product number
- CS-7825
- Product name
- Vedolizumab
- Purity
- 99.64%
- Packaging
- 5mg
- Price
- $740
- Updated
- 2021/12/16
- Product number
- ATB0023426
- Product name
- VEDOLIZUMAB
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $996.68
- Updated
- 2021/12/16
- Product number
- CS-7825
- Product name
- Vedolizumab
- Purity
- 99.64%
- Packaging
- 25mg
- Price
- $2800
- Updated
- 2021/12/16
Vedolizumab Chemical Properties,Usage,Production
Uses
Vedolizumab is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
Clinical Use
Monoclonal antibody:
Treatment of ulcerative colitis and Crohn’s disease
in vivo
Blockade of α4β7 receptors on T-lymphocytes has been shown to occur for several weeks after a single dose of vedolizumab. The drug concentration following the infusion has been shown to be dose related with a mean maximum concentration of 12.5 μg/mL in those receiving 0.5 mg/kg of vedolizumab and 52.0 μg/mL in those receiving 2 mg/kg. The serum half-life of these two doses is 9-12 days respectively and saturation of α4β7 receptors on T-lymphocytes is >90% at both 4-6 weeks following infusion. In a dose ranging study, the serum drug concentrations increase with increasing dose and when regular induction infusions are used (on day 1, 15, 29 and 85), the serum half-life is between 15 and 22 days across all groups[1].
Drug interactions
Potentially hazardous interactions with other drugs
Live vaccines: risk of generalised infections - avoid.
Metabolism
The expected consequence of metabolism is proteolytic degradation to small peptides and individual amino acids, and receptor-mediated clearance. The exact elimination route of vedolizumab is unknown although renal clearance is expected to be negligible.
References
[1] Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. DOI:10.1124/jpet.109.153973
[2] Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7(1):4-9. DOI:10.4103/0976-9668.175016
Vedolizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Vedolizumab Suppliers
- Tel
- --
- Fax
- --
- sales@carbosynth.com
- Country
- United Kingdom
- ProdList
- 6005
- Advantage
- 58